<DOC>
	<DOCNO>NCT00000752</DOCNO>
	<brief_summary>To evaluate additional effectiveness anti-inflammatory nasal spray ( beclomethasone dipropionate ) broad spectrum antibiotic ( cefuroxime axetil ) decongestant ( Deconsal II ) alone , agent give individually combination prevention recurrent paranasal sinus infection patient HIV infection . To compare clinical utility paranasal sinus radiograph compute tomograms ( CTs ) evaluation management HIV-infected patient recurrent paranasal sinus infection . To determine relevant prognostic factor microbiologic etiology maxillary sinusitis patient population . Sinusitis common among HIV-infected patient likely recurrent refractory traditional therapy , particularly patient advanced immunosuppression . An intervention aim prevention recurrent sinus disease HIV-infected patient appear warranted .</brief_summary>
	<brief_title>Preventing Frequent Sinus Infections HIV-Infected Patients</brief_title>
	<detailed_description>Sinusitis common among HIV-infected patient likely recurrent refractory traditional therapy , particularly patient advanced immunosuppression . An intervention aim prevention recurrent sinus disease HIV-infected patient appear warranted . Patients receive 21-42 day antibiotic therapy define episode sinusitis . Following discontinuation antibiotic , screen evaluation perform . Within 7 day follow completion antibiotic , patient clinical resolution begin 14 +/- 3 day decongestant therapy oral Deconsal II , drug combine pseudoephedrine , decongestant , guaifenesin , expectorant . Following decongestant therapy , patient undergo entry evaluation , include nasal endoscopy sinus radiograph . Patients continue clinical resolution purulence endoscopy randomize receive decongestant alone combination nasal steroid ( beclomethasone dipropionate ) antibiotic ( cefuroxime axetil ) . Treatment continue minimum 52 week maximum 104 week . Patients follow week 4 , 8 , 12 every 8 week thereafter .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Phenylpropanolamine</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Guaifenesin</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<mesh_term>Chlorpheniramine , phenylpropanolamine drug combination</mesh_term>
	<mesh_term>Cefuroxime axetil</mesh_term>
	<mesh_term>Cefuroxime</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretroviral agent ( approved investigational ) . Biologic response modifier . Systemic chemotherapy . Chemoprophylaxis Pneumocystis carinii pneumonia ( PCP ) , candidiasis , herpes . Adjuvant systemic corticosteroid appropriate antibiotic therapy moderate severe PCP . Maintenance therapy pyrimethamine , sulfadiazine , amphotericin B , fluconazole , ketoconazole , acyclovir . Treatment ganciclovir , foscarnet , antimycobacterial drug CMV disease mycobacterial infection . Nonbeta lactam antibacterial agent infection ( beta lactam antibacterial agent allow study drug temporarily discontinue ) . Antihistamines saline nasal spray . Concurrent Treatment : Allowed : Radiation therapy . Patients must : HIV infection . At least one episode symptomatic maxillary sinusitis , clinical resolution follow antibiotic therapy . Life expectancy least 12 month . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Concurrent infection cause cytomegalovirus Mycobacterium avium Complex . Significant emotional disorder psychosis . Conditions dementia would substantially impair study compliance . Evidence significant malabsorption , ileus , significant emesis would inhibit drug absorption . Inability tolerate minimum administration one tablet oral Deconsal II daily . Concurrent Medication : Excluded : Prescription overthecounter nasal steroid , decongestant , topical vasoconstrictor ( ephedrine , oxymetazoline ) . Patients follow prior condition exclude : History acute hypersensitivity reaction penicillin cephalosporin , characterize urticaria , hypotension , laryngeal edema . Active substance abuse would impair study compliance .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>cefuroxime axetil</keyword>
	<keyword>Beclomethasone</keyword>
	<keyword>Guaiacol Glyceryl Ether</keyword>
	<keyword>Sinusitis</keyword>
	<keyword>Ephedrine</keyword>
</DOC>